Elan reported fourth-quarter profit of $169.5 million, or 36 cents a share, as sales of multiple sclerosis drug Tysabri soared.
More: continued here
Elan reported fourth-quarter profit of $169.5 million, or 36 cents a share, as sales of multiple sclerosis drug Tysabri soared.
More: continued here